董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hansoo Michael Keyoung | 男 | Independent Director | 51 | 7.24万美元 | 0.56 | 2026-06-29 |
| Hyun W. Bae | 男 | Independent Director | 56 | 6.24万美元 | 4.99 | 2026-06-29 |
| Rahul Singhvi | 男 | Independent Director | 60 | 6.88万美元 | 0.56 | 2026-06-29 |
| John S. Yu | 男 | Chairman of the Board and Chief Executive Officer and Director | 61 | 36.29万美元 | 534.72 | 2026-06-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Doug Samuelson | 男 | Chief Financial Officer | 66 | 25.48万美元 | 未持股 | 2026-06-29 |
| Neil Bhowmick | 男 | Chief Scientific Officer | 54 | 22.54万美元 | 113.53 | 2026-06-29 |
| Ramachandran Murali | 男 | Vice President of Research and Development | 65 | 19.04万美元 | 14.22 | 2026-06-29 |
| John S. Yu | 男 | Chairman of the Board and Chief Executive Officer and Director | 61 | 36.29万美元 | 534.72 | 2026-06-29 |
董事简历
中英对照 | 中文 | 英文- Hansoo Michael Keyoung
-
Hansoo Michael Keyoung自2019年7月起担任我们的董事会成员。自2017年8月以来，Keyoung博士一直担任CBC Group（原名C-Bridge Capital，一家专注于梦百合的私募股权公司，管理着超过20亿美元的资产）的董事总经理兼北美主管。Keyoung博士自2013年11月起担任Portola Capital Partners LLC（一家专注于梦百合的投资和咨询公司）的创始管理合伙人。Keyoung博士曾于2015年7月至2017年8月担任临床阶段生物技术公司Genexine Inc.的总裁兼首席执行官。在此之前，Keyoung博士于2013年12月至2015年6月担任Catalyst Biosciences Inc.（一家血友病和眼科为重点的临床阶段公司）的亚洲区总裁，并担任Burrill&Company LLC（一家风险投资公司）的董事总经理兼泛亚主管，从2008年到2013年，他监管私人和公共生物技术和医疗技术公司的投资。Keyoung博士在Cornell University Weill Medical College，Memorial Sloan Kettering Cancer Center和the Rockefeller University获得神经科学和神经学的医学博士学位和博士学位，作为三机构医学博士-博士项目奖学金获得者。目前，Keyoung博士在Affamed Therapeutics担任董事会主席和成员，在InxMed担任董事会成员，并担任Everest Medicines Ltd.和i-mab Biopharma US Ltd.的创始董事会成员。
Hansoo Michael Keyoung has served on Kairos Pharma, Ltd.'s Board as an independent director since Kairos Pharma, Ltd.'s IPO in September 2024. For over 20 years, Dr. Keyoung has led a successful career as a physician, healthcare executive, and investor in the United States, Europe and Asia. Since 2017, Dr. Keyoung has served as the head of North America for CBC Group, a healthcare dedicated private equity firm with over $4 billion in assets under management. He has served as Board Chair of AffaMed Therapeutics since 2019, a director of Graybug Vision, a Nasdaq listed company, since 2019, and a director of InxMed since 2019. From 2015 to 2017, Dr. Keyoung also served as the Chief Executive Officer of Genexine, a KOSDAQ listed biotech company with a $1 billion plus market cap focused on developing innovative biologic drugs for cancer and rare diseases. During his tenure as Chief Executive Officer of Genexine, he successfully helped lead clinical development in Europe and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma. From 2013 to 2015, he also served as President of Catalyst Biosciences, a Nasdaq listed company and a clinical stage hemophilia and ophthalmology company that partnered with Pfizer, MedImmune, and Isu Abxis. Additionally, he has experience advising Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial partnership strategies. Dr. Keyoung has a Doctor of Medicine degree and a Doctor of Philosophy degree in neuroscience and neurology from Cornell University Weill Medical College and Memorial Sloan Kettering. He was also a Biomedical Fellow at Rockefeller University and Memorial Sloan Kettering. - Hansoo Michael Keyoung自2019年7月起担任我们的董事会成员。自2017年8月以来，Keyoung博士一直担任CBC Group（原名C-Bridge Capital，一家专注于梦百合的私募股权公司，管理着超过20亿美元的资产）的董事总经理兼北美主管。Keyoung博士自2013年11月起担任Portola Capital Partners LLC（一家专注于梦百合的投资和咨询公司）的创始管理合伙人。Keyoung博士曾于2015年7月至2017年8月担任临床阶段生物技术公司Genexine Inc.的总裁兼首席执行官。在此之前，Keyoung博士于2013年12月至2015年6月担任Catalyst Biosciences Inc.（一家血友病和眼科为重点的临床阶段公司）的亚洲区总裁，并担任Burrill&Company LLC（一家风险投资公司）的董事总经理兼泛亚主管，从2008年到2013年，他监管私人和公共生物技术和医疗技术公司的投资。Keyoung博士在Cornell University Weill Medical College，Memorial Sloan Kettering Cancer Center和the Rockefeller University获得神经科学和神经学的医学博士学位和博士学位，作为三机构医学博士-博士项目奖学金获得者。目前，Keyoung博士在Affamed Therapeutics担任董事会主席和成员，在InxMed担任董事会成员，并担任Everest Medicines Ltd.和i-mab Biopharma US Ltd.的创始董事会成员。
- Hansoo Michael Keyoung has served on Kairos Pharma, Ltd.'s Board as an independent director since Kairos Pharma, Ltd.'s IPO in September 2024. For over 20 years, Dr. Keyoung has led a successful career as a physician, healthcare executive, and investor in the United States, Europe and Asia. Since 2017, Dr. Keyoung has served as the head of North America for CBC Group, a healthcare dedicated private equity firm with over $4 billion in assets under management. He has served as Board Chair of AffaMed Therapeutics since 2019, a director of Graybug Vision, a Nasdaq listed company, since 2019, and a director of InxMed since 2019. From 2015 to 2017, Dr. Keyoung also served as the Chief Executive Officer of Genexine, a KOSDAQ listed biotech company with a $1 billion plus market cap focused on developing innovative biologic drugs for cancer and rare diseases. During his tenure as Chief Executive Officer of Genexine, he successfully helped lead clinical development in Europe and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma. From 2013 to 2015, he also served as President of Catalyst Biosciences, a Nasdaq listed company and a clinical stage hemophilia and ophthalmology company that partnered with Pfizer, MedImmune, and Isu Abxis. Additionally, he has experience advising Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial partnership strategies. Dr. Keyoung has a Doctor of Medicine degree and a Doctor of Philosophy degree in neuroscience and neurology from Cornell University Weill Medical College and Memorial Sloan Kettering. He was also a Biomedical Fellow at Rockefeller University and Memorial Sloan Kettering.
- Hyun W. Bae
-
Hyun W. Bae，自2020年9月9日起担任Kairos Pharma，Ltd.董事会独立董事。裴博士目前是Cedars-Sinai医疗中心的骨科外科教授，Cedars教育和奖学金项目主任，以及骨科干细胞和组织工程实验室的临床合作伙伴。自2010年以来，裴博士一直担任Prosidyan的首席医疗官和董事，Prosidyan是一家开发基于纤维的生物活性玻璃专利产品的公司。裴博士自2008年起担任Mesoblast的科学顾问委员会成员，自2018年起担任Engage Surgical，自2019年起担任Spine Biopharma。2008年至2015年，他还担任Tissuegene的科学顾问委员会成员。裴博士是一位在药物开发行业工作了20年的资深人士，也是一位著名的研究员和发明家。他是FDA批准的四项随机临床试验的首席研究员，在他的整个职业生涯中完成了30项临床研究。裴博士还撰写了60篇已发表的科学论文，撰写了5篇评论文章，并拥有30项专利。裴博士在哥伦比亚大学获得生物力学学位，在耶鲁大学以优异成绩获得医学博士学位，曾任马里兰州贝塞斯达的NIH Howard Hughes研究员。
Hyun W. Bae has served on Kairos Pharma, Ltd.'s Board as an independent director since September 9, 2020. Dr. Bae is an orthopaedic surgeon in private practice in Santa Monica, California, and has been appointed Professor in Orthopaedic Surgery at Cedars Sinai Medical Center, the Director of Cedars' Education and Fellowship program, and a clinical partner of the Orthopaedic Stem Cell and Tissue Engineering Laboratory. Since 2010, Dr. Bae has served as the Chief Medical Officer and a director of Prosidyan, a company that develops proprietary fiber based bioactive glass products. Dr. Bae has served as a Scientific Advisory Board Member of Mesoblast since 2008, Engage Surgical since 2018, and Spine Biopharma since 2019. He also served as a Scientific Advisory Board Member of Tissuegene from 2008 to 2015. Dr. Bae is a 20 year veteran of the drug development industry and is a renowned researcher and inventor. He was principal investigator for four FDA approved randomized clinical trials and has completed 30 clinical studies throughout his career. Dr. Bae also has authored 60 published scientific papers, written five review articles and holds 30 patents. Dr. Bae obtained a Biomechanics degree from Columbia University and a Doctor of Medicine degree, cum laude, from Yale University and is a former NIH Howard Hughes Research Fellow in Bethesda. - Hyun W. Bae，自2020年9月9日起担任Kairos Pharma，Ltd.董事会独立董事。裴博士目前是Cedars-Sinai医疗中心的骨科外科教授，Cedars教育和奖学金项目主任，以及骨科干细胞和组织工程实验室的临床合作伙伴。自2010年以来，裴博士一直担任Prosidyan的首席医疗官和董事，Prosidyan是一家开发基于纤维的生物活性玻璃专利产品的公司。裴博士自2008年起担任Mesoblast的科学顾问委员会成员，自2018年起担任Engage Surgical，自2019年起担任Spine Biopharma。2008年至2015年，他还担任Tissuegene的科学顾问委员会成员。裴博士是一位在药物开发行业工作了20年的资深人士，也是一位著名的研究员和发明家。他是FDA批准的四项随机临床试验的首席研究员，在他的整个职业生涯中完成了30项临床研究。裴博士还撰写了60篇已发表的科学论文，撰写了5篇评论文章，并拥有30项专利。裴博士在哥伦比亚大学获得生物力学学位，在耶鲁大学以优异成绩获得医学博士学位，曾任马里兰州贝塞斯达的NIH Howard Hughes研究员。
- Hyun W. Bae has served on Kairos Pharma, Ltd.'s Board as an independent director since September 9, 2020. Dr. Bae is an orthopaedic surgeon in private practice in Santa Monica, California, and has been appointed Professor in Orthopaedic Surgery at Cedars Sinai Medical Center, the Director of Cedars' Education and Fellowship program, and a clinical partner of the Orthopaedic Stem Cell and Tissue Engineering Laboratory. Since 2010, Dr. Bae has served as the Chief Medical Officer and a director of Prosidyan, a company that develops proprietary fiber based bioactive glass products. Dr. Bae has served as a Scientific Advisory Board Member of Mesoblast since 2008, Engage Surgical since 2018, and Spine Biopharma since 2019. He also served as a Scientific Advisory Board Member of Tissuegene from 2008 to 2015. Dr. Bae is a 20 year veteran of the drug development industry and is a renowned researcher and inventor. He was principal investigator for four FDA approved randomized clinical trials and has completed 30 clinical studies throughout his career. Dr. Bae also has authored 60 published scientific papers, written five review articles and holds 30 patents. Dr. Bae obtained a Biomechanics degree from Columbia University and a Doctor of Medicine degree, cum laude, from Yale University and is a former NIH Howard Hughes Research Fellow in Bethesda.
- Rahul Singhvi
-
Rahul Singhvi博士是Novavax公司的总裁兼首席执行官。自2005年8月开始，他一直担任Novavax公司的董事。2005年4月至2005年8月，他曾担任Novavax公司的高级副总裁兼首席运营官。2004年4月至2005年4月，他曾担任药物开发和制造业务副主管。在加入本公司之前10年，Singhvi博士在默克公司（Merck & Co.）担任多个职位，最终作为默克生产部总监（1999至2004年）。
Rahul Singhvi has served on Kairos Pharma, Ltd.'s board of directors as an independent director since December 10, 2024. Dr. Singhvi is a global leader in the Life Sciences industry and is cofounder of the US based biomanufacturing company, Resilience (National Resilience, Inc.). Prior to cofounding Resilience in 2020, from October 2019 to July 2020, Dr. Singhvi was an Operating Partner at Flagship Pioneering, where he founded and operated companies launched from Flagship's innovation foundry, Flagship Venture Labs. Before joining Flagship, from September 2013 until October 2019, Rahul was the Chief Operating Officer at the Vaccine Business Unit of Takeda Pharmaceutical Co Ltd. (NYSE: TAK) where he led worldwide vaccine manufacturing operations. Before joining Takeda, from August 2005 to April 2011, Dr. Singhvi was President and CEO of Novavax, Inc. (Nasdaq:NVAX) where he led the company's transformation into a global vaccine player. Dr. Singhvi's career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing. Dr. Singhvi serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq:CDXS), and Garuda Therapeutics (private). Dr. Singhvi graduated as the top ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained both his M.S. and Sc.D. degrees in chemical engineering from MIT. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar. Because of Dr. Signhvi's experience and knowledge in the operation and leadership of early stage public healthcare companies, Kairos Pharma, Ltd. - Rahul Singhvi博士是Novavax公司的总裁兼首席执行官。自2005年8月开始，他一直担任Novavax公司的董事。2005年4月至2005年8月，他曾担任Novavax公司的高级副总裁兼首席运营官。2004年4月至2005年4月，他曾担任药物开发和制造业务副主管。在加入本公司之前10年，Singhvi博士在默克公司（Merck & Co.）担任多个职位，最终作为默克生产部总监（1999至2004年）。
- Rahul Singhvi has served on Kairos Pharma, Ltd.'s board of directors as an independent director since December 10, 2024. Dr. Singhvi is a global leader in the Life Sciences industry and is cofounder of the US based biomanufacturing company, Resilience (National Resilience, Inc.). Prior to cofounding Resilience in 2020, from October 2019 to July 2020, Dr. Singhvi was an Operating Partner at Flagship Pioneering, where he founded and operated companies launched from Flagship's innovation foundry, Flagship Venture Labs. Before joining Flagship, from September 2013 until October 2019, Rahul was the Chief Operating Officer at the Vaccine Business Unit of Takeda Pharmaceutical Co Ltd. (NYSE: TAK) where he led worldwide vaccine manufacturing operations. Before joining Takeda, from August 2005 to April 2011, Dr. Singhvi was President and CEO of Novavax, Inc. (Nasdaq:NVAX) where he led the company's transformation into a global vaccine player. Dr. Singhvi's career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing. Dr. Singhvi serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq:CDXS), and Garuda Therapeutics (private). Dr. Singhvi graduated as the top ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained both his M.S. and Sc.D. degrees in chemical engineering from MIT. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar. Because of Dr. Signhvi's experience and knowledge in the operation and leadership of early stage public healthcare companies, Kairos Pharma, Ltd.
- John S. Yu
-
John S. Yu Kairos Pharma, Ltd.联合创始人、董事长兼首席执行官，是一名医学临床医生和调查员。2007年1月以来，担任董事会主席。2012年8月到2012年11月，他还担任临时首席执行官。自1997年以来，他是Cedars-Sinai Medical Center神经外科学系的全职教员。他是一个国际著名的神经外科医生，其临床研究重点是治疗恶性和良性的大脑和脊髓肿瘤。他还在免疫和基因领域进行广泛的研究，用于治疗脑瘤。他还深度研究过以神经干细胞作为运载工具，治疗大脑癌症和神经退行性疾病。2005年，他入选了Castle and Connelly America Top Doctors。他在许多著名期刊上发表过很多文章，包括The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science和 Journal of Neurosurgery。他取得了斯坦福大学法国文学学位和生物科学学士学位，还花了一年时间在巴黎Sorbonne学院学习法国文学。他也在巴黎 Institut Pasteur获得过免疫学奖学金。他取得了哈佛医学院医学学位和哈佛大学遗传学硕士学位。他在波士顿马萨诸塞州总医院担任了神经外科住院医师。此外，从1988年到1989年，他在国家心理健康研究所担任神经科学研究员；从1993年到1995年，他还是马萨诸塞州总医院神经免疫学和分子神经遗传学部门的学者。他的其他荣誉包括：Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995。1996年，他获得了美国神经外科学会的Academy Award。其他荣誉还包括：2000年的Congress of Neurological Surgeons 的Young Investigator Awardin奖、2001 年的National Brain Tumor Foundation Grant奖以及2005年American Association of Neurological Surgeons 的the Mahaley Clinical Research award奖。
John S. Yu is a medical clinician and investigator. Since 2019, Dr. Yu has also served as the Chief Financial Officer and a director of Kairos Pharma, Ltd.'s wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos's pipeline to tackle the most unmet needs in cancer – resistance to cancer therapeutics and the suppressed immune response in cancer. As the Professor of Neurosurgery and Director of Surgical Neuro Oncology at Cedars Sinai Medical Center, where he has worked since January 1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr. Yu is the co inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor's degree from Stanford University in 1985 and spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology at the Institut Pasteur in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master's degree from the Harvard University Department of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital in Boston. His portfolio has included 26 research grants, 10 patents, seven FDA approved investigational drugs and 17 IRB approved clinical trials. - John S. Yu Kairos Pharma, Ltd.联合创始人、董事长兼首席执行官，是一名医学临床医生和调查员。2007年1月以来，担任董事会主席。2012年8月到2012年11月，他还担任临时首席执行官。自1997年以来，他是Cedars-Sinai Medical Center神经外科学系的全职教员。他是一个国际著名的神经外科医生，其临床研究重点是治疗恶性和良性的大脑和脊髓肿瘤。他还在免疫和基因领域进行广泛的研究，用于治疗脑瘤。他还深度研究过以神经干细胞作为运载工具，治疗大脑癌症和神经退行性疾病。2005年，他入选了Castle and Connelly America Top Doctors。他在许多著名期刊上发表过很多文章，包括The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science和 Journal of Neurosurgery。他取得了斯坦福大学法国文学学位和生物科学学士学位，还花了一年时间在巴黎Sorbonne学院学习法国文学。他也在巴黎 Institut Pasteur获得过免疫学奖学金。他取得了哈佛医学院医学学位和哈佛大学遗传学硕士学位。他在波士顿马萨诸塞州总医院担任了神经外科住院医师。此外，从1988年到1989年，他在国家心理健康研究所担任神经科学研究员；从1993年到1995年，他还是马萨诸塞州总医院神经免疫学和分子神经遗传学部门的学者。他的其他荣誉包括：Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995。1996年，他获得了美国神经外科学会的Academy Award。其他荣誉还包括：2000年的Congress of Neurological Surgeons 的Young Investigator Awardin奖、2001 年的National Brain Tumor Foundation Grant奖以及2005年American Association of Neurological Surgeons 的the Mahaley Clinical Research award奖。
- John S. Yu is a medical clinician and investigator. Since 2019, Dr. Yu has also served as the Chief Financial Officer and a director of Kairos Pharma, Ltd.'s wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos's pipeline to tackle the most unmet needs in cancer – resistance to cancer therapeutics and the suppressed immune response in cancer. As the Professor of Neurosurgery and Director of Surgical Neuro Oncology at Cedars Sinai Medical Center, where he has worked since January 1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr. Yu is the co inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor's degree from Stanford University in 1985 and spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology at the Institut Pasteur in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master's degree from the Harvard University Department of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital in Boston. His portfolio has included 26 research grants, 10 patents, seven FDA approved investigational drugs and 17 IRB approved clinical trials.
高管简历
中英对照 | 中文 | 英文- Doug Samuelson
Doug Samuelson自2023年1月起担任Genelux公司首席财务官。Samuelson先生于2022年9月至2023年1月担任Genelux公司财务副总裁，并自2021年1月起担任本公司顾问。Samuelson先生于2016年至2023年1月在Wellness Center USA，Inc.担任兼职首席财务官。在此之前，Samuelson先生于2016年9月至2020年3月担任Second Sight Medical Products，Inc.的会计总监。2018年1月至2019年6月，他还担任AdvaVet，Inc.的首席财务官，并于2014年至2016年担任Solis Tek，Inc.的首席财务官，于2011年至2014年担任Medacta USA，Inc.的首席财务官，并于2010-2011年担任Response Genetics，Inc.的临时首席财务官及会计和财务报告总监。萨缪尔森先生在犹他大学获得会计学学士学位，在北岭加州州立大学获得计算机科学硕士学位。
Doug Samuelson has served as Kairos Pharma, Ltd.'s external Chief Financial Officer since 2019. Mr. Samuelson is a finance and accounting professional with over 25 years of experience. From 2016 to 2022, Mr. Samuelson served as the Chief Financial Officer of Wellness Center USA, Inc. in Tucson, Arizona. From 2016 to March 2020, Mr. Samuelson served as the Director of Accounting of Second Sight Medical Products, Inc., and in this position, managed all accounting functions, including all general ledger close functions, tax reporting, external audit responsibilities, banking and technical accounting issues. From 2018 to 2019, Mr. Samuelson served as the Chief Financial Officer of AdvaVet, Inc., in Los Angeles, California, the U.S. subsidiary of Swedish pharmaceutical company, Oasmia Pharmaceutical AB (NASDAQ: OASM). From 2016 to 2018, Mr. Samuelson was the Chief Financial Officer of Solis Tek, Inc. (OTC: GNAL), where he handled all financial reporting with the SEC. Mr. Samuelson obtained a Bachelor of Science in Accounting from University of Utah, College of Business, and obtained a Master of Science in Computer Science from California State University, Northridge, School of Engineering. He is also a Certified Public Accountant in the State of California.- Doug Samuelson自2023年1月起担任Genelux公司首席财务官。Samuelson先生于2022年9月至2023年1月担任Genelux公司财务副总裁，并自2021年1月起担任本公司顾问。Samuelson先生于2016年至2023年1月在Wellness Center USA，Inc.担任兼职首席财务官。在此之前，Samuelson先生于2016年9月至2020年3月担任Second Sight Medical Products，Inc.的会计总监。2018年1月至2019年6月，他还担任AdvaVet，Inc.的首席财务官，并于2014年至2016年担任Solis Tek，Inc.的首席财务官，于2011年至2014年担任Medacta USA，Inc.的首席财务官，并于2010-2011年担任Response Genetics，Inc.的临时首席财务官及会计和财务报告总监。萨缪尔森先生在犹他大学获得会计学学士学位，在北岭加州州立大学获得计算机科学硕士学位。
- Doug Samuelson has served as Kairos Pharma, Ltd.'s external Chief Financial Officer since 2019. Mr. Samuelson is a finance and accounting professional with over 25 years of experience. From 2016 to 2022, Mr. Samuelson served as the Chief Financial Officer of Wellness Center USA, Inc. in Tucson, Arizona. From 2016 to March 2020, Mr. Samuelson served as the Director of Accounting of Second Sight Medical Products, Inc., and in this position, managed all accounting functions, including all general ledger close functions, tax reporting, external audit responsibilities, banking and technical accounting issues. From 2018 to 2019, Mr. Samuelson served as the Chief Financial Officer of AdvaVet, Inc., in Los Angeles, California, the U.S. subsidiary of Swedish pharmaceutical company, Oasmia Pharmaceutical AB (NASDAQ: OASM). From 2016 to 2018, Mr. Samuelson was the Chief Financial Officer of Solis Tek, Inc. (OTC: GNAL), where he handled all financial reporting with the SEC. Mr. Samuelson obtained a Bachelor of Science in Accounting from University of Utah, College of Business, and obtained a Master of Science in Computer Science from California State University, Northridge, School of Engineering. He is also a Certified Public Accountant in the State of California.
- Neil Bhowmick
Neil Bhowmick Kairos Pharma，Ltd.首席科学官，拥有超过20年的广泛生物化学经验，在治疗和设备领域申请和起诉专利，发表在同行评审期刊（110篇出版物）上，领导基础和临床前癌症研究，获得监管批准，并进行临床试验。Bhowmick发现了成纤维细胞在癌症治疗耐药性中的作用，作为Enviro Therapeutics Inc的创始人和首席执行官，Kairos Pharma，Ltd.编辑了这一发现，在临床前和临床实例中延长了多种癌症类型的癌症缓解时间。他在范德堡大学接受培训，是Cedars-Sinai医学中心的医学教授和Cedars-Sinai癌症生物学项目的主任。他是四本科学期刊的编辑委员会成员，也是美国国立卫生研究院资助研究部门的特许成员。Bhowmick博士曾于2009年在Celgene（现为Bristol Myers Squibb，一家在纽约证券交易所上市的公司）担任顾问，2019年至2020年在纳斯达克上市的Xencor公司担任顾问，2014年至2019年在纳斯达克上市的Tracon公司担任顾问。他目前是FibroBiologics科学顾问委员会的成员。Bhowmick博士获得NCI/NIH资助超过15年，被引用超过15,000次，并拥有六项生物标志物检测平台和基质靶向疗法专利（包括ENV 105和ENV 205）。
Neil Bhowmick has more than 20 years of broad biochemistry experience filing and prosecuting patents in therapeutics and devices, published in peer reviewed journals (110 publications) leading foundational and pre clinical cancer studies, obtaining regulatory approvals, and conducting clinical trials. Dr. Bhowmick discovered the role of fibroblasts in cancer therapy resistance and has used this finding to extend the time of cancer remission in multiple cancer types in preclinical and clinical examples as a founder and CEO of Enviro Therapeutics Inc. He trained at Vanderbilt University and is the Professor of Medicine at Cedars Sinai Medical Center and Director of the Cancer Biology Program at Cedars Sinai Cancer. He is on the Editorial Board of four scientific journals and charter member of a NIH grant study section. Dr. Bhowmick was a Consultant at Celgene (currently Bristol Myers Squibb, a New York Stock Exchange listed company) in 2009, Xencor Inc., a Nasdaq listed company, from 2019 to 2020 and at Tracon, a Nasdaq listed company, from 2014 to 2019. He currently serves on the Scientific Advisory Board of FibroBiologics. Dr. Bhowmick has received NCI/NIH funding for over 15 years, has been cited over 15,000 times, and holds six patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV 105 and ENV 205).- Neil Bhowmick Kairos Pharma，Ltd.首席科学官，拥有超过20年的广泛生物化学经验，在治疗和设备领域申请和起诉专利，发表在同行评审期刊（110篇出版物）上，领导基础和临床前癌症研究，获得监管批准，并进行临床试验。Bhowmick发现了成纤维细胞在癌症治疗耐药性中的作用，作为Enviro Therapeutics Inc的创始人和首席执行官，Kairos Pharma，Ltd.编辑了这一发现，在临床前和临床实例中延长了多种癌症类型的癌症缓解时间。他在范德堡大学接受培训，是Cedars-Sinai医学中心的医学教授和Cedars-Sinai癌症生物学项目的主任。他是四本科学期刊的编辑委员会成员，也是美国国立卫生研究院资助研究部门的特许成员。Bhowmick博士曾于2009年在Celgene（现为Bristol Myers Squibb，一家在纽约证券交易所上市的公司）担任顾问，2019年至2020年在纳斯达克上市的Xencor公司担任顾问，2014年至2019年在纳斯达克上市的Tracon公司担任顾问。他目前是FibroBiologics科学顾问委员会的成员。Bhowmick博士获得NCI/NIH资助超过15年，被引用超过15,000次，并拥有六项生物标志物检测平台和基质靶向疗法专利（包括ENV 105和ENV 205）。
- Neil Bhowmick has more than 20 years of broad biochemistry experience filing and prosecuting patents in therapeutics and devices, published in peer reviewed journals (110 publications) leading foundational and pre clinical cancer studies, obtaining regulatory approvals, and conducting clinical trials. Dr. Bhowmick discovered the role of fibroblasts in cancer therapy resistance and has used this finding to extend the time of cancer remission in multiple cancer types in preclinical and clinical examples as a founder and CEO of Enviro Therapeutics Inc. He trained at Vanderbilt University and is the Professor of Medicine at Cedars Sinai Medical Center and Director of the Cancer Biology Program at Cedars Sinai Cancer. He is on the Editorial Board of four scientific journals and charter member of a NIH grant study section. Dr. Bhowmick was a Consultant at Celgene (currently Bristol Myers Squibb, a New York Stock Exchange listed company) in 2009, Xencor Inc., a Nasdaq listed company, from 2019 to 2020 and at Tracon, a Nasdaq listed company, from 2014 to 2019. He currently serves on the Scientific Advisory Board of FibroBiologics. Dr. Bhowmick has received NCI/NIH funding for over 15 years, has been cited over 15,000 times, and holds six patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV 105 and ENV 205).
- Ramachandran Murali
Ramachandran Murali Kairos Pharma，Ltd.研发副总裁，是一位知名的结构生物学家，在大分子晶体学、计算生物学、药物发现、免疫学和癌症生物学方面拥有专长。利用这些技能，穆拉利博士开发了一种独特的技术，用于开发小肽模拟物和小分子药物，这些药物针对蛋白质-蛋白质/DNA相互作用，用于癌症生物学、免疫疗法和自身免疫病理学等领域的诊断和治疗应用。穆拉利博士与人共同创立了三家生物技术初创公司，包括1996年在华盛顿州西雅图成立的癌症免疫治疗公司Xcyte Therapeutics，2003年在宾夕法尼亚州费城成立的免疫治疗制药公司Ception Therapeutics，以及2005年在加利福尼亚州洛杉矶成立的免疫治疗公司Nidus。Murali博士的成就还包括为众多细胞表面受体复合物开发小分子激动剂/拮抗剂，其中包括TNFR超级家族的成员。最近，他针对多种转录因子，如Onecut-2，进行癌症治疗。Murali博士在与多家生物技术公司合作方面拥有超过10年的经验，并且是10多项专利的共同发明人。Murali博士在马德拉斯大学获得生物物理学博士学位，马德拉斯大学是印度结构生物学的先驱机构之一。毕业后，他在哥伦比亚大学和Wistar研究所（宾夕法尼亚州费城）完成了博士后培训。后来，他以教员的身份加入宾夕法尼亚大学，并升任副教授。他目前是Cedars-Sinai医疗中心（加利福尼亚州洛杉矶）免疫学研究部生物医学科学系教授。
Ramachandran Murali is an established structural biologist with expertise in macromolecular crystallography, computational biology, drug discovery, immunology, and cancer biology. Using these skills, Dr. Murali advanced a unique technology for creating small peptidomimetics and small molecule drugs that target protein protein/DNA interactions for diagnostic and therapeutic applications in areas like cancer biology, immunotherapy, and autoimmune pathologies. Dr. Murali co founded three biotech startup companies, including Xcyte Therapeutics, a cancer immunotherapy company founded in Seattle, WA in 1996, Ception Therapeutics, Inc, an immunotherapeutic pharmaceutical company founded in Philadelphia, PA in 2003 and Nidus, CA, a immunotherapeutic company founded in Los Angeles, CA in 2005. Dr. Murali's accomplishments also include developing small molecule agonist/antagonists for numerous cell surface receptor complexes, including members of the TNFR super family. Recently, he targeted various transcription factors, such as Onecut 2, for cancer therapy. Dr. Murali has over 10 years of experience in collaborating with several biotech companies and is a co inventor of more than 10 patents. Dr. Murali obtained his doctoral degree in Biophysics from the University of Madras, one of the pioneering institutes for structural biology in India. Upon graduation, he completed his post doctoral training at Columbia University and the Wistar Institute (Philadelphia, PA). Later, he joined the University of Pennsylvania as a faculty member and rose to the position of Associate Professor. He is currently a Professor in the Department of Biomedical Sciences, Research Division of Immunology at Cedars Sinai Medical Center (Los Angeles, CA).- Ramachandran Murali Kairos Pharma，Ltd.研发副总裁，是一位知名的结构生物学家，在大分子晶体学、计算生物学、药物发现、免疫学和癌症生物学方面拥有专长。利用这些技能，穆拉利博士开发了一种独特的技术，用于开发小肽模拟物和小分子药物，这些药物针对蛋白质-蛋白质/DNA相互作用，用于癌症生物学、免疫疗法和自身免疫病理学等领域的诊断和治疗应用。穆拉利博士与人共同创立了三家生物技术初创公司，包括1996年在华盛顿州西雅图成立的癌症免疫治疗公司Xcyte Therapeutics，2003年在宾夕法尼亚州费城成立的免疫治疗制药公司Ception Therapeutics，以及2005年在加利福尼亚州洛杉矶成立的免疫治疗公司Nidus。Murali博士的成就还包括为众多细胞表面受体复合物开发小分子激动剂/拮抗剂，其中包括TNFR超级家族的成员。最近，他针对多种转录因子，如Onecut-2，进行癌症治疗。Murali博士在与多家生物技术公司合作方面拥有超过10年的经验，并且是10多项专利的共同发明人。Murali博士在马德拉斯大学获得生物物理学博士学位，马德拉斯大学是印度结构生物学的先驱机构之一。毕业后，他在哥伦比亚大学和Wistar研究所（宾夕法尼亚州费城）完成了博士后培训。后来，他以教员的身份加入宾夕法尼亚大学，并升任副教授。他目前是Cedars-Sinai医疗中心（加利福尼亚州洛杉矶）免疫学研究部生物医学科学系教授。
- Ramachandran Murali is an established structural biologist with expertise in macromolecular crystallography, computational biology, drug discovery, immunology, and cancer biology. Using these skills, Dr. Murali advanced a unique technology for creating small peptidomimetics and small molecule drugs that target protein protein/DNA interactions for diagnostic and therapeutic applications in areas like cancer biology, immunotherapy, and autoimmune pathologies. Dr. Murali co founded three biotech startup companies, including Xcyte Therapeutics, a cancer immunotherapy company founded in Seattle, WA in 1996, Ception Therapeutics, Inc, an immunotherapeutic pharmaceutical company founded in Philadelphia, PA in 2003 and Nidus, CA, a immunotherapeutic company founded in Los Angeles, CA in 2005. Dr. Murali's accomplishments also include developing small molecule agonist/antagonists for numerous cell surface receptor complexes, including members of the TNFR super family. Recently, he targeted various transcription factors, such as Onecut 2, for cancer therapy. Dr. Murali has over 10 years of experience in collaborating with several biotech companies and is a co inventor of more than 10 patents. Dr. Murali obtained his doctoral degree in Biophysics from the University of Madras, one of the pioneering institutes for structural biology in India. Upon graduation, he completed his post doctoral training at Columbia University and the Wistar Institute (Philadelphia, PA). Later, he joined the University of Pennsylvania as a faculty member and rose to the position of Associate Professor. He is currently a Professor in the Department of Biomedical Sciences, Research Division of Immunology at Cedars Sinai Medical Center (Los Angeles, CA).
- John S. Yu
John S. Yu Kairos Pharma, Ltd.联合创始人、董事长兼首席执行官，是一名医学临床医生和调查员。2007年1月以来，担任董事会主席。2012年8月到2012年11月，他还担任临时首席执行官。自1997年以来，他是Cedars-Sinai Medical Center神经外科学系的全职教员。他是一个国际著名的神经外科医生，其临床研究重点是治疗恶性和良性的大脑和脊髓肿瘤。他还在免疫和基因领域进行广泛的研究，用于治疗脑瘤。他还深度研究过以神经干细胞作为运载工具，治疗大脑癌症和神经退行性疾病。2005年，他入选了Castle and Connelly America Top Doctors。他在许多著名期刊上发表过很多文章，包括The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science和 Journal of Neurosurgery。他取得了斯坦福大学法国文学学位和生物科学学士学位，还花了一年时间在巴黎Sorbonne学院学习法国文学。他也在巴黎 Institut Pasteur获得过免疫学奖学金。他取得了哈佛医学院医学学位和哈佛大学遗传学硕士学位。他在波士顿马萨诸塞州总医院担任了神经外科住院医师。此外，从1988年到1989年，他在国家心理健康研究所担任神经科学研究员；从1993年到1995年，他还是马萨诸塞州总医院神经免疫学和分子神经遗传学部门的学者。他的其他荣誉包括：Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995。1996年，他获得了美国神经外科学会的Academy Award。其他荣誉还包括：2000年的Congress of Neurological Surgeons 的Young Investigator Awardin奖、2001 年的National Brain Tumor Foundation Grant奖以及2005年American Association of Neurological Surgeons 的the Mahaley Clinical Research award奖。
John S. Yu is a medical clinician and investigator. Since 2019, Dr. Yu has also served as the Chief Financial Officer and a director of Kairos Pharma, Ltd.'s wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos's pipeline to tackle the most unmet needs in cancer – resistance to cancer therapeutics and the suppressed immune response in cancer. As the Professor of Neurosurgery and Director of Surgical Neuro Oncology at Cedars Sinai Medical Center, where he has worked since January 1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr. Yu is the co inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor's degree from Stanford University in 1985 and spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology at the Institut Pasteur in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master's degree from the Harvard University Department of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital in Boston. His portfolio has included 26 research grants, 10 patents, seven FDA approved investigational drugs and 17 IRB approved clinical trials.- John S. Yu Kairos Pharma, Ltd.联合创始人、董事长兼首席执行官，是一名医学临床医生和调查员。2007年1月以来，担任董事会主席。2012年8月到2012年11月，他还担任临时首席执行官。自1997年以来，他是Cedars-Sinai Medical Center神经外科学系的全职教员。他是一个国际著名的神经外科医生，其临床研究重点是治疗恶性和良性的大脑和脊髓肿瘤。他还在免疫和基因领域进行广泛的研究，用于治疗脑瘤。他还深度研究过以神经干细胞作为运载工具，治疗大脑癌症和神经退行性疾病。2005年，他入选了Castle and Connelly America Top Doctors。他在许多著名期刊上发表过很多文章，包括The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science和 Journal of Neurosurgery。他取得了斯坦福大学法国文学学位和生物科学学士学位，还花了一年时间在巴黎Sorbonne学院学习法国文学。他也在巴黎 Institut Pasteur获得过免疫学奖学金。他取得了哈佛医学院医学学位和哈佛大学遗传学硕士学位。他在波士顿马萨诸塞州总医院担任了神经外科住院医师。此外，从1988年到1989年，他在国家心理健康研究所担任神经科学研究员；从1993年到1995年，他还是马萨诸塞州总医院神经免疫学和分子神经遗传学部门的学者。他的其他荣誉包括：Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995。1996年，他获得了美国神经外科学会的Academy Award。其他荣誉还包括：2000年的Congress of Neurological Surgeons 的Young Investigator Awardin奖、2001 年的National Brain Tumor Foundation Grant奖以及2005年American Association of Neurological Surgeons 的the Mahaley Clinical Research award奖。
- John S. Yu is a medical clinician and investigator. Since 2019, Dr. Yu has also served as the Chief Financial Officer and a director of Kairos Pharma, Ltd.'s wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos's pipeline to tackle the most unmet needs in cancer – resistance to cancer therapeutics and the suppressed immune response in cancer. As the Professor of Neurosurgery and Director of Surgical Neuro Oncology at Cedars Sinai Medical Center, where he has worked since January 1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr. Yu is the co inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor's degree from Stanford University in 1985 and spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology at the Institut Pasteur in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master's degree from the Harvard University Department of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital in Boston. His portfolio has included 26 research grants, 10 patents, seven FDA approved investigational drugs and 17 IRB approved clinical trials.